Skip to main content

Table 3 Antimicrobial activity against respiratory Pseudomonas aeruginosa isolates by region (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Region Antimicrobial MIC (mg/L) %S + %Ia %R
MIC90 Range
Africa/Middle East
(n = 471)
Piperacillin-tazobactam 128 0.25–≥256 73.5 26.5
Aztreonam 32 0.06–≥256 79.8 20.2
Ceftazidime 64 0.12–≥256 79.0 21.0
Ceftazidime-avibactam 8 ≤0.015–≥256 91.9 8.1
Cefepime 32 ≤0.12–≥64 76.6 23.4
Imipenem ≥16 0.06–≥16 66.7 33.3
Meropenemb 16 0.015–≥32 82.8 17.2
Levofloxacin ≥16 0.03–≥16 65.2 34.8
Colistin 2 0.12–4 99.8 0.2
Amikacin 16 ≤0.25–≥128 92.1 7.9
Asia/South Pacific
(n = 1007)
Piperacillin-tazobactam 128 ≤0.12–≥256 72.7 27.3
Aztreonam 32 ≤0.015–≥256 79.5 20.5
Ceftazidime 64 0.06–≥256 76.3 23.7
Ceftazidime-avibactam 8 ≤0.015–≥256 93.4 6.6
Cefepime 32 ≤0.12–≥64 79.3 20.7
Imipenem ≥16 0.12–≥16 80.1 19.9
Meropenemb 8 0.008–≥32 90.1 9.9
Levofloxacin ≥16 0.008–≥16 66.7 33.3
Colistin 2 ≤0.06–≥16 99.2 0.8
Amikacin 8 ≤0.25–≥128 95.6 4.4
Europe
(n = 3049)
Piperacillin-tazobactam 128 ≤0.12–≥256 69.2 30.8
Aztreonam 32 0.03–≥256 76.5 23.5
Ceftazidime 64 0.06–≥256 74.0 26.0
Ceftazidime-avibactam 8 ≤0.015–≥256 91.0 9.0
Cefepime 32 ≤0.12–≥64 76.0 24.0
Imipenem ≥16 ≤0.03–≥16 69.3 30.7
Meropenemb 16 0.008–≥32 83.1 16.9
Levofloxacin ≥16 0.015–≥16 59.9 40.1
Colistin 1 ≤0.06–≥16 99.7 0.3
Amikacin 32 ≤0.25–≥128 89.8 10.2
Latin America
(n = 805)
Piperacillin-tazobactam 128 0.25–≥256 69.3 30.7
Aztreonam 64 0.06–≥256 75.9 24.1
Ceftazidime 128 0.06–≥256 71.2 28.8
Ceftazidime-avibactam 32 0.03–≥256 85.7 14.3
Cefepime 32 ≤0.12–≥64 72.3 27.7
Imipenem ≥16 0.12–≥16 62.6 37.4
Meropenemb 16 ≤0.004–≥32 76.6 23.4
Levofloxacin ≥16 0.015–≥16 60.7 39.3
Colistin 1 ≤0.06–≥16 99.5 0.5
Amikacin 64 ≤0.25–≥128 82.4 17.6
  1. MIC minimum inhibitory concentration; MIC90 MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant
  2. aIncludes all isolates not in the resistant category for all antimicrobial agents
  3. bThe breakdown of meropenem %S and %I data is: Africa/Middle East, 67.5% (%S) and 15.3% (%I); Asia/South Pacific, 79.7% (%S) and 10.3% (%I); Europe, 69.5% (%S) and 13.6% (%I); Latin America, 63.0% (%S) and 13.7% (%I)